We are focused on revolutionizing medicine by developing product candidates for a range of severe diseases leveraging CRISPR expertise and other core technologies and therapeutic approaches.
Programs
Program
Indication
Indication
Research and
Preclinical
Preclinical
Early-Stage
Clinical
Clinical
Late-Stage
Clinical
Clinical
Partners
REGV131-LNP1265 Hemophilia B3
Research and
Preclinical
Preclinical
AVC-201 & AVC-203 Acute Myeloid Leukemia & B-Cell Malignancies4
Early-Stage
Clinical
Clinical
Other Ongoing Research Programs Various5
Research
- Lead refers to lead development and commercial party.
1. Lonvo-z (lonvoguran ziclumeran), formerly referred to as NTLA-2002. 2. Nex-z (nexiguran ziclumeran), formerly referred to as NTLA-2001; Regeneron shares 25% of worldwide development costs and commercial profits for the ATTR program and has an option to enter into a co-promotion agreement for the U.S. commercialization. 3. Hemophilia B is being advanced solely by Regeneron; Intellia is eligible for milestones and royalties. 4. AVC-201 and AVC-203 are wholly owned by AvenCell and utilize proprietary allogeneic cell engineering technology licensed from Intellia. 5. Intellia is advancing both wholly owned and partnered programs.
Download
